/Biogen%20Inc%20logo%20on%20HQ-by%20Tada%20Images%20via%20Shutterstock.jpg)
Analysts are maintaining a generally positive outlook on Biogen's shares, noting recent stock strength and solid operational results.
/Bio-Techne%20Corp%20logo%20and%20data-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Although Bio-Techne has underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
/Moderna%20Inc%20meds-by%20Ascannio%20via%20Shutterstock.jpg)
While Moderna has outpaced the S&P 500 over the past year, Wall Street analysts maintain a cautious outlook about the stock’s prospects.
Our senior market strategist explains which ETFs offer exposure to high-powered biotech growth, without T. Rex-sized risk.
/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Regeneron Pharmaceuticals has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.
/Incyte%20Corp_%20phone%20and%20logo-by%20T_Schneider%20via%20Shutterstock.jpg)
Incyte has delivered better returns than the broader market over the past year, and analysts view the stock’s outlook with measured optimism.
/Bio-Techne%20Corp%20site%20magnified%20-by%20Pavel%20Kapysh%20via%20Shutterstock.jpg)
Despite underperforming the broader market and biotechnology industry over the past year, analysts remain strongly bullish on Bio-Techne’s longer-term prospects.
Hunting for upside potential typically reserved for the private equity world? Look no further.
Regeneron’s stock has fallen behind the broader market over the past year, but analysts see potential for growth, tempered with caution.
/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
Incyte has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.